Bristol Myers Squibb Reports Positive Interim Phase 3 ACTION-1 Results for RYZ101
Bristol Myers Squibb announced positive topline results from an interim analysis of the Phase 3 ACTION-1 study of RYZ101 in patients with GEP-NETs.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
REG — BioPharma Credit PLC — Half — year Financial Report
For best results when printing this announcement, please click on link below: RNS Number: 0622W BioPharma Credit PLC 24 September 2026 24 September 2026 BIOPHARMA CREDIT PLC ("BPCR" or "the Company") HALF YEAR REPORT FOR THE YEAR ENDED 30 JUNE 2026 BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt inv